drugset
drugset / Trial / NCT03051386

Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults

NCT03051386 ↗

Phase 2 Unknown 500 enrolled U.S. Army Medical Research and Development Command US Army Medical Research Institute of Infectious Diseases · collab
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of VEE vaccine, Live, Attenuated, dried TC-83, NDBR 102, Lot 4, Run 3, and collect data on the incidence of occupational VEE virus infection in vaccinated personnel.

Timeline

Start
2018-05-30
Primary completion
2022-04-01
Completion
2023-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject VEE Vaccine Vaccine 0.5 ml Subcutaneous

Indications

Venezuelan equine encephalitis